임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 22:40
논문번호 68
논문제목(영문) Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Ahn Y
교신저자명 Jeong MH
공동저자명 Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK;
게제년월일 2007-09-21
ISSN 1346-9843
Impact Factor 3.940
학술지명 Circulation journal
서지사항 0집 / 72권 / 1호,   페이지(35 - 39)
요약초록문
(Abstract) 입력		 BACKGROUND:
Previous studies have shown that cilostazol may not only prevent stent thrombosis, but may also have positive effect in the prevention of restenosis. However, the effect of cilostazol on restenosis after successful deployment of drug-eluting stent (DES) in patients with diabetes mellitus has not been evaluated.
METHODS AND RESULTS:
A total of 280 patients at 8 clinical sites were randomized. The patients (61.7+/-9.9 years old, 163 males) who underwent successful stenting were randomized to aspirin and cilostazol (group I, n=141, 61.2+/-9.6 years old) vs aspirin and clopidogrel (group II, n=139, 62.0+/-10.0 years old) after 1 month of aspirin, cilostazol, and clopidogrel combination treatment. There were no significant differences in baseline characteristics of the groups. The type of DES implanted did not differ between the groups. There were no differences in angiographic and procedural characteristics of the groups. Major adverse cardiac events, including acute and subacute stent thrombosis within 1 month, did not occur in either group. Cases of angiographic late stent thrombosis were 1 (0.9%) in group I and 1 (0.8%) in group II. Follow-up coronary angiography was performed in 237 patients (84.6%). Mean follow-up duration was 7.1 months. The rate of angiographic restenosis (stent plus 5-mm borders) was 9 (8.0%) in group I and 20 (16.1%) in group II, p=0.041). The minimal luminal diameter at follow-up period in group I was 2.55+/-0.63 mm compared with 2.41+/-0.83 mm in group II (p=NS).
CONCLUSIONS:
Combination therapy with aspirin and cilostazol for the prevention of stent restenosis is comparable or superior to that of aspirin and clopidogrel in diabetic patients who undergo DES implantation.
파일  C68.+Circ+J.+2008;72(1)35-39..pdf (63.0K) DATE : 2021-05-21 16:51:47